Today's conditional marketing authorisation in the European Union of the new protease inhibitor (PI) darunavir (boosted with ritonivir) provides physicians with the opportunity to build a potent new treatment combination with the fusion inhibitor, FUZEON.

Today's positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) of Tibotec's boosted protease inhibitor darunavir is good news for HIV treatment-experienced patients facing drug resistance.